Optimization of Ultra-High-Throughput Screening Assay for D-Allulose 3-Epimerase Protein Engineering

Faster Screening, Better Enzymes

If you buy or formulate D-allulose, enzyme performance is the whole game. Better enzymes mean lower production costs and cleaner labels. This paper from Biomolecules (DOI: 10.3390/biom12111547) shows how to find those better enzymes faster.

The problem with DAEase

D-allulose is the C-3 epimer of D-fructose. It tastes similar to sucrose but with a fraction of the calories. Food makers use it in bakery, beverages, and confections. Producing it depends on D-allulose 3-epimerase, or DAEase. Most natural DAEase variants are not thermostable enough for industrial conditions. High reaction temperatures speed conversion and reduce contamination risk, but they destroy the enzyme.

Directed evolution can fix that. The problem is screening. When you generate millions of mutant enzymes, you need a fast, reliable way to separate winners from losers. Traditional assays are too slow. The research team optimized a PsiR-based ultra-high-throughput screening assay to close that gap. PsiR is a genetic element that senses D-allulose. When the enzyme converts D-fructose into D-allulose, the system produces a detectable readout. Researchers can sort through huge libraries quickly and pick out the active variants.

What the researchers did

The team applied this screen to DAEase directed evolution. They isolated a beneficial single mutant, I228V, with improved specific activity and thermostability. Then they stacked additional mutations onto that backbone.

The final triple mutant, I228V/D281G/C289R, delivered a big jump in performance. The numbers tell the story.

Key results

Variant	Specific activity	Half-life at 60°C	D-fructose conversion at 70°C
Wild-type	1.0x baseline	1.0x baseline	21.64%
Triple mutant I228V/D281G/C289R	1.42x wild-type	62.97x longer	28.11%

That 62.97x half-life gain is enormous. The enzyme survives nearly 63 times longer under heat stress. In a production process, that means more batches per enzyme charge, less downtime, and lower enzyme cost. Specific activity also rose 42%. The enzyme works faster, too.

The biosynthesis experiment confirmed the practical advantage. At 70°C, the triple mutant converted 28.11% of D-fructose into D-allulose. Wild-type converted 21.64%. That is a real difference in a real reaction, not just an assay artifact.

Why this matters for manufacturers

The economics of D-allulose hinge on enzyme turnover, thermostability, and conversion yield. This triple mutant improves all three. Higher thermostability allows higher operating temperatures. Higher temperatures reduce contamination pressure and improve reaction kinetics. Longer enzyme life cuts the amount of enzyme needed per kilogram of product.

For ingredient buyers, this points toward more cost-competitive supply as the technology scales. Better conversion also means less residual fructose to manage. That can simplify downstream processing and improve yield consistency.

For formulators, the sweetener itself does not change. But suppliers who adopt variants like I228V/D281G/C289R can produce D-allulose more efficiently. That may eventually show up in price and availability.

The study also proves the screening method works. PsiR-based ultra-high-throughput screening can accelerate development of other rare-sugar enzymes. Faster screening means more enzyme generations per year. More generations mean faster progress toward industrial performance.

FAQ

Is PsiR-based screening limited to D-allulose?
PsiR senses D-allulose, so the assay works best for enzymes that make D-allulose. Similar logic could apply to other rare sugars if the right sensor exists.

Does this paper mean D-allulose gets cheaper now?
No. This is lab-scale protein engineering. Commercial adoption depends on fermentation yields, scale-up, and regulatory approval. But it moves the cost curve in the right direction.

What does a 62.97x half-life gain actually look like?
At 60°C, the triple mutant remains active far longer than wild-type. The exact processing time depends on enzyme loading and substrate conditions, but the stability gap is large enough to change process design.

The next step is industrial translation. Someone needs to put this mutant into a production strain and run pilot trials. That takes time. But the science is clear: better DAEase variants exist, and we now have faster ways to find them.